TC Biopharm Holdings PLC

TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company was founded by Michael Leek and Angela Scott in 2013 and is headquartered in Motherwell, the United Kingdom.

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EDINBURGH, Scotland , May 6, 2024 /PRNewswire/ -- TC BioPharm (Holdings) plc ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,750,000 of the Company's American Depositary Shares (the "ADSs") originally issued in December 2023 with an exercise price of £1.5814 per ADS and a term of five years. Each ADS represents twenty ordinary shares of the Company.

TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds

TC BioPharm (NASDAQ: TCBP ) stock is rocketing higher on Monday after the clinical-stage biopharmaceutical company announced a major deal to acquire another company. According to a press release from TC BioPharm, it intends to acquire a private biotechnology company developing Chimeric Antigen Receptor T-cell (CAR-T) therapies.

Why Is TC Biopharm (TCBP) Stock Up 51% Today?

Acquisition target has established  proof of concept data demonstrating the therapeutic potential for the treatment of multiple solid tumors EDINBURGH, Scotland , May 6, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent to acquire a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies for the treatment of refractory cancers and solid tumors. This agreement is the second such agreement in as many months shows TCBP's commitment to its M&A strategy aimed at expanding its therapeutic platform.

TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies

TC BioPharm (NASDAQ: TCBP ) stock is heading higher on Thursday after the company announced an acquisition that would beef up its therapeutic platform. According to a news report, TC BioPharm has executed a non-binding letter of intent for the proprietary manufacturing process of two allogeneic CAR-NK therapeutics.

Why Is TC Biopharm (TCBP) Stock Up 78% Today?

EDINBURGH, Scotland , April 4, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent as part of its M&A strategy aimed at expanding its therapeutic platform and leveraging NK (natural killer) cells in treating both solid tumors and other indications. The target asset acquisition covers the proprietary manufacturing process of two allogeneic CAR-NK therapeutics, both of which TCB believes are valuable as monotherapies as well as in conjunction with TCB-008 in the future.

TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies

Developing streamlined approach to reduce cost per patient by 85% EDINBURGH, Scotland , April 2, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it is developing a streamlined and scaled-up manufacturing process which will increase its treatments capacity from 52 patient treatments per year to more than 1,000.  This undertaking, which will utilize its current infrastructure, will provide a cost reduction of 85% per patient treatment.

TCBP Increasing Treatment Capacity with Expanded Manufacturing Process

EDINBURGH, Scotland , March 19, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has adjourned its General Meeting of the Company to a later date.  TC BioPharm is awaiting clarity on additional information of a material matter related to the shareholder vote.

TCBP Adjourns General Meeting Until a Later Date

•  Company receives gross proceeds of $1.26 M from transaction EDINBURGH, Scotland , March 18, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that an institutional investor has exercised cash only warrants represented 623,750 American Depository Shares (ADS) at an exercise price of $2.02. The gross proceeds of the warrant exercise was $1,263,000 with a net cash infusion of $1,168,275 to the Company post fees associated with the exercise to HC Wainwright & Co. There was no additional consideration or inducement paid for the exercise of the Series D warrants in this transaction.

TCBP Announces Exercise of Series D Warrants For Cash

EDINBURGH, Scotland , March 1, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that Chief Executive Officer, Bryan Kobel was again featured on a live interview on "The Big Biz Show," an Emmy Award-winning nationally syndicated TV and radio show.   Bryan Kobel, CEO stated, "It was great to reconnect with 'Sully' and his crew in order to provide an update on all the exciting developments that are going on at TC BioPharm.

Bryan Kobel, CEO of TCBP, Appears on Nationally Syndicated "The Big Biz Show"

EDINBURGH, Scotland , Feb. 27, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the company will host a shareholder update call on Tuesday, March 5th, 2024, at 10:00 am EST. Management intends to provide a brief update on the Company's operations, clinical trials as well as insight on the company's 2024 outlook and discuss business development efforts.

TCBP Announces Shareholder Update Call on March 5th 2024

Increases dose level in line with Cohort 2 in IND Changes from "in patient" to "out patient" procedure EDINBURGH, Scotland , Feb. 22, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the MHRA has officially accepted its proposed amendment to the Company's clinical trial authorisation (CTA). The amendment allows for an increase in dosing size of TCB008 (unmodified expanded gamma delta T cell Lymphocytes) to 12x10^7-23x10^7 gamma delta t-cells.

TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial

EDINBURGH, Scotland , Feb. 15, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that CEO, Bryan Kobel and Process Development Manager, Dr. Lauren Bor will be featured "Expert Speakers" at the 7th 7th CAR-TCR Summit Europe, February 27-29 th in London, UK. Cell therapy industry experts will unite in for the only cell therapy conference looking in-depth at boosting clinical durability, advancing predictive biomarkers, and implementing safety switches through to automating production and accelerating analytical processes to reduce operational costs and turnaround times; and new cell therapy technology.

TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe

Provies update on Prelininary Proxy Statement Filing Highlights Approximate $11.6 M cost-savings EDINBURGH, Scotland , Feb. 14, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced a shareholder update with a projected outlook for the current year. "The previous year was a time of significant operational achievement for TC BioPharm," said Bryan Kobel, Chief Executive Officer.

TCBP Provides Shareholder Update and Highlights Upcoming Milestones

EDINBURGH, Scotland , Jan. 29, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced that its Chief Executive Officer, Bryan Kobel, was featured in live interview with the "Big Biz Show," an Emmy Award-winning nationally syndicated TV and radio show. Click here for Interview:   https://www.youtube.com/watch?v=oAUXEBV20oo&t=41s The interview will be aired on cable TV and streaming services, including Roku, as well as on radio via The Biz Talk Radio Network, Armed Forces Radio, and iHeart Media in 175 countries.

TC BioPharm Chief Executive Officer, Bryan Kobel Featured on 'The Big Biz Show'

EDINBURGH, Scotland , Jan. 18, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced its participation at the upcoming Sequire Investor Summit 2024 scheduled for January 23-25, 2024 at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. TC BioPharm CEO, Bryan Kobel, will conduct in person one-on-one meetings throughout the conference and deliver the Company's presentation to registered participants as shown below.

TC BioPharm to Present at the Sequire Investor Summit

EDINBURGH, Scotland , Jan. 4, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced that on January 2, 2024, the Company received a written notice from The Nasdaq Stock Market ("Nasdaq"). The notice informed TC BioPharm that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) (the "Rule") for continued listing on the Nasdaq Capital Market.

TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement

Cost saving moves are being made to extend runway and prioritize primary goal of clinical success The company is launching the initiative with the target of a reduction in cash-burn at the Company by approximately 50% to become fully effective in Q1 2024 EDINBURGH, Scotland, Jan. 3, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced that the Company is undertaking a series of initiatives to reduce costs and drive efficiency in order to reduce cash burn and expand its financial runway. TC BioPharm's Overhead Reduction Plan includes: Scaled down Research and Development to strictly process development for commercial applications and manufacturing Implementing a focused manufacturing platform targeting only product needed to complete ACHIEVE trial in 2024  Further streamlining the organization to drive process-related efficiencies.

TC BioPharm Announces Additional Cost Reduction Steps to Improve Financial Standing and Streamline Efficiencies

EDINBURGH, Scotland , Dec. 22, 2023 /PRNewswire/ -- TC BioPharm (Holdings) plc ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the closing of its previously announced public offering of 1,750,000 of its American Depositary Shares (the "ADSs") (or pre-funded warrants in lieu thereof), together with Series E warrants (the "Series E Warrants") to purchase up to 1,750,000 of its ADSs at a public offering price of $2.00 per ADS (or pre-funded warrant in lieu thereof) and associated Series E Warrant. The Series E Warrants have an exercise price of £1.5814 per ADS, are exercisable upon issuance and will expire five years following the date of issuance.

TC BioPharm Announces Closing of $3.5 Million Public Offering

EDINBURGH, Scotland , Dec. 19, 2023 /PRNewswire/ -- TC BioPharm (Holdings) plc ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the pricing of a public offering of 1,750,000 of its American Depositary Shares (the "ADSs") (or pre-funded warrants in lieu thereof), together with Series E warrants (the "Series E Warrants") to purchase up to 1,750,000 of its ADSs at a public offering price of $2.00 per ADS (or pre-funded warrant in lieu thereof) and associated Series E Warrant. The Series E Warrants will have an exercise price of £1.5814 per ADS, are exercisable upon issuance and will expire five years following the date of issuance.

TC BioPharm Announces Pricing of $3.5 Million Public Offering

EDINBURGH, Scotland , Dec. 18, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today that the creation of a new Commercial Development Division, which will be headed by Dr. Lauren Bor, PhD. The new division will focus on optimizing production of TCB-008 in anticipation of ACHIEVE data in 2024 as well as the recent IND clearance for TCB-008 in the US, and preparing a clear regulatory path for commercialization, as well as the research of new and developing technologies for future efficiencies in the manufacturing process.

TC BioPharm Announces Formation of Commercial Development Division, Led by Industry Veteran, Dr. Lauren Bor Ph.D

EDINBURGH, Scotland , Dec. 13, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today that it will change its ratio of its American Depositary Shares ("ADSs") to ordinary shares from one (1) ADS representing one (1) ordinary share to one ADS representing twenty (20) ordinary shares (the "ADS Ratio Change"). The ADS Ratio Change is expected to become effective on or about December 15, 2023, U.S. Eastern Time (the " Effective Date").

TC BioPharm Announces Plan to Implement ADS Ratio Change

The FDA clears TC BioPharm's (TCBP) investigational new drug application seeking approval to begin a clinical study on its pipeline candidate, TCB008, for treating acute myeloid leukemia. Stock declines.

TC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug

EDINBURGH, Scotland , Nov. 27, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today that the FDA  provides clearance on the Company's investigational new drug (IND) application for a Phase 1B study in relapse/refractory Acute Myeloid Leukemia (AML). The Phase 1B study, dubbed ACHIEVE2, will be a 9 patient, dose escalating study measuring for safety and dose optimization.

TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia

No Significant Safety Concerns Observed in Safety Cohort Management expects to expand ACHIEVE trial in Q1 EDINBURGH, Scotland , Nov. 14, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announces today that the Company has successfully completed its Safety Cohort and received positive review from the Data Safety Monitoring Board (DSMB). The DSMB review was held after completion of enrollment of the initial cohort of the ACHIEVE trial and examined the safety data from all patients enrolled to ensure of no dose limiting toxicities or drug related serious adverse events.

TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results

Creates economic leverage with vertical integration of database and management EDINBURGH, Scotland , Nov. 2, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today that it has selected of Fortrea (FTRE) as the Company's Contract Research Organization (CRO) for global trials, including ACHIEVE and ACHIEVE2. The trials, in the UK and US respectively, will be managed by Fortrea on an ongoing basis, creating a vertically integrated clinical trial program which allows for increased operational efficiencies, resulting in better data management and review as well as value creation.

News for TC Biopharm Holdings PLC Stock (TCBP)